To earn credit, a pre-test is required. Click here to access activity pre-test:
If you do not want to earn credit but want to view the video, read the activity overview below.
It is required you read the activity overview. Once you have scrolled to the end, click to confirm, and you will be able to watch the video.
Overview of Thyroid Carcinoma and the Expanding Treatment Landscape
Filmed on October 31, 2014
at JADPRO Live at APSHO 2014
A continuing education activity for nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses.
Meniscus Educational Institute
Advanced Practitioner Society of Hematology and Oncology
© 2014, Meniscus Educational Institute. All rights reserved.
Carolyn Grande, CRNP, AOCNP®
Hospital of the University of Pennsylvania
Department of Otorhinolaryngology
Abramson Cancer Center
ACTIVITY RATIONALE AND PURPOSE
Thyroid cancer is a highly treatable disease that occurs more than three times as often in women than men. Approximately 80% of thyroid cancers have 10+ year survival rates of over 90%, making long-term care and treatment adherence critical issues for these patients. Advanced practitioners (APs) have a key role as long-term patients’ point of contact for tumor progress assessment, education regarding treatment, and re-evaluation of tumor status. This session reviews the different types of thyroid carcinomas and highlights the role of the AP in the treatment spectrum.
The activity’s target audience will consist of nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, oncology and hematology nurses, pharmacists, and physicians.
After completing this educational activity, participants should be able to:
Statement of Credit—Participants who successfully complete this activity (including completion of the post-test with a passing score of at least 70% and evaluation form) will receive a statement of credit.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Meniscus Educational Institute and Advanced Practitioners Society for Hematology and Oncology (APSHO) and JADPRO. The Meniscus Educational Institute is accredited by the ACCME to provide continuing medical education for physicians.
The Meniscus Educational Institute designates this enduring webcast for a maximum of 0.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity for 0.75 contact hours is provided by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
Provider approved by the California Board of Registered Nursing, Provider No. 13164, for 0.75 contact hours.
The knowledge-based accredited education lectures are intended for pharmacists involved in the care of cancer patients. This educational activity is sponsored by the Meniscus Educational Institute.
The Meniscus Educational Institute is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. The ACPE Universal Activity Number assigned to this program, for 0.75 contact hours, is 0429-9999-15-012-H01-P.
Any participant wanting to file a grievance with respect to any aspect of a continuing pharmacy education activity accredited by Meniscus Educational Institute (MEI) may contact MEI in writing at 3131 Princeton Pike, Bldg 1B Suite 205A, Lawrenceville, NJ 08648. A written response will be provided within 30 days of receiving the written statement. If the participant is unsatisfied with the response, an appeal to the Executive Vice President, MEI may be made for a second level of review.
All individuals in positions to control the content of this activity (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this continuing education activity. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Carolyn Grande, CRNP, AOCNP, has received funds for research from Bayer Healthcare Pharmaceuticals, Eisai, Inc., Exelixis, Inc., Novartis Pharmaceuticals, and Roche Pharmaceuticals.
Jeannine Coronna has nothing to disclose.
Claudine Kiffer has nothing to disclose.
Terry Logan, CHCP, has nothing to disclose.
Molly Thompson has nothing to disclose.
Lynn Rubin has nothing to disclose.
Pamela Hallquist Viale, RN, MS, CS, ANP, has nothing to disclose.
Lead Nurse Planner
Rita Wickham, PhD, RN, AOCN®, has received honoraria from Genentech.
Wendy Smith, Wendy J Smith, RN, MSN, ACNP, AOCN, has nothing to disclose.
Glen J. Bingle, MD, PhD has nothing to disclose.
Christopher Campen, PharmD, BCPS, BCOP has owned stock from Abbvie.
Rita Wickham, PhD, RN, AOCN® has received honoraria from Genentech.
This activity has been designed to provide continuing education that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Meniscus Educational Institute educational
opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population.
The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Meniscus Educational Institute of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
I confirm that I have read the above information.
If you do not want to earn credit but want to view the video, click here: